Nautilus Biotechnology, Inc. (NAUT) Balance Sheet
As of 2026-06-30 (10-Q), Nautilus Biotechnology, Inc. (NAUT) reported total assets of $163.6M, total liabilities of $32.5M and shareholders' equity of $131.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $13.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAUTNautilus Biotechnology, Inc.Follow NAUT — free
—
Price chart with a free account
- Market cap
- 412.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 36.6 | 185.6 | 114.5 | 19.4 | 27.6 | 12.4 | 13.2 | |
| Short-term investments | 40.1 | 160.1 | 69.9 | 154.0 | 102.2 | 91.0 | 70.9 | |
| Inventory | — | — | — | — | — | — | 0.6 | |
| Current assets | 77.7 | 349.2 | 187.2 | 176.8 | 132.8 | 106.0 | 87.6 | |
| Total assets | 85.0 | 398.5 | 350.1 | 305.6 | 242.7 | 191.1 | 163.6 | |
| Current liabilities | 3.0 | 5.8 | 6.8 | 9.1 | 7.6 | 8.0 | 8.6 | |
| Total liabilities | 6.3 | 34.9 | 35.1 | 40.2 | 34.0 | 34.1 | 32.5 | |
| Shareholders' equity | -29.7 | 363.6 | 314.9 | 265.4 | 208.7 | 157.0 | 131.1 |
USD millions · SEC XBRL
Nautilus Biotechnology, Inc. — questions
- How much cash does Nautilus Biotechnology, Inc. have?
- $13.2M in cash and cash equivalents as of 2026-06-30.
- What are Nautilus Biotechnology, Inc.'s total assets?
- $163.6M as of 2026-06-30.
- What is Nautilus Biotechnology, Inc.'s shareholders' equity?
- $131.1M as of 2026-06-30.
Every figure on this page comes from Nautilus Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.